Front page
Nothing from your lists
What covered companies filed with the SEC, day by day.
Nothing from your lists
+ 3 more
Nothing from your lists
Woodward, Inc. · “On September 15, 2026, the Board of Directors of Woodward, Inc. (the “Company”) approved a plan to transition production out of its Santa Clarita, California, facility to streamline its portfolio and refine its manufacturing footprint.”¶1
Clearwater Paper Corp · “Clearwater Paper Corporation (NYSE: CLW) today announced the successful refinancing of its senior notes due in 2028, along with the refinancing of both its existing term revolver credit facility and its existing ABL revolving credit facility.”¶1
National CineMedia, Inc. · “The transaction closed on September 18, 2026 following the receipt of regulatory approval and satisfaction of other closing conditions.”¶1
Nothing from your lists
Nothing from your lists
Nothing from your lists
Nothing from your lists
On September 15, 2026, Algorhythm completed its acquisition of substantially all of Azure Energy, LLC’s assets and certain liabilities through Azure Holdings, LLC.¶1¶2
The $23,000,000 purchase price consisted of 4,076,312 shares of Common Stock and 22,038 shares of Series B Preferred Stock.¶3¶4
The Company exchanged 3,500 shares of Series A Preferred Stock held by Streeterville for PPP #5 with an original principal amount of $4,025,000, bearing interest at 9% per annum.¶5¶6
Effective September 15, 2026, the Board appointed Andrew Thompson as Chief Executive Officer and Chairman, Ryan J. Smith as Chief Operating Officer, and Leticia Raele as Chief Accounting Officer and Interim Chief Financial Officer.
On September 17, 2026, Sangamo completed the sale of assets primarily related to ST-920 to PTC Therapeutics, Inc. for $111,000,000 in cash, up to $100,000,000 in contingent consideration, and assumed liabilities.¶1
Sangamo filed a voluntary Chapter 11 petition on June 23, 2026, and completed the asset sale while continuing to operate as a debtor-in-possession.¶2¶1
Nasdaq filed a Form 25 on September 17, 2026, and Sangamo’s delisting from Nasdaq will become effective on September 27, 2026.¶3
The Company intends to restate its 2025 Form 10-K and applicable 2025 and 2026 Form 10-Q financial statements, along with corresponding CSC Holdings, LLC statements.¶1¶2¶3
The restatements are expected to reduce previously reported net losses by approximately $430 million for periods ended September 30, 2025, and approximately $720 million for periods ended June 30, 2026.¶4¶5
Management expects to report a material weakness in internal control over financial reporting related to accounting for income taxes during the affected periods.¶6
Woodward will move military fixed-wing and rotorcraft flight control actuation production to Spartanburg, South Carolina, and sell certain legacy product lines and the Santa Clarita campus.¶1¶2
The Company estimates cumulative pre-tax charges of $34 million to $47.5 million, including employee-related costs of $23 million to $29 million and contract termination costs of $10 million to $16.5 million.¶3
Woodward expects Santa Clarita operations to cease no later than December 2027, and the decision is expected to affect about 400 roles at the facility.¶4¶5
On September 18, 2026, Clearwater Paper entered into a Second Amended and Restated Credit Agreement replacing its existing term revolver and ABL credit facilities.¶2
The agreement provides a $200 million revolving loan commitment, with $15 million drawn, and a $275 million term loan commitment, fully drawn at closing.¶3
Using the refinancing proceeds, the company deposited funds to redeem its $275 million 2028 Notes on October 3, 2026, paid $1.7 million accrued interest, and terminated the ABL Credit Agreement.¶4¶5¶6
On September 18, 2026, NCM Holdings, LLC completed the acquisition of Captivate Holdings, LLC and Captivate Network Holdings, Inc., acquiring 100.0% of Captivate’s issued and outstanding equity interests for $275.0 million.¶2¶3¶4
The Company funded the acquisition, refinancing and related fees with a $275.0 million term loan, a $25.0 million revolving facility, and $10.0 million borrowed under the revolving facility.¶5¶6
The Company repaid all outstanding obligations under its existing credit facility, terminated its commitments, released related liens and security interests, and discharged all guarantees.¶7¶8
On September 15, 2026, the Company redeemed all outstanding Series A Preferred Stock at a redemption price of $965 per share, for a cumulative redemption amount of approximately $5,790,000.¶2
On September 18, 2026, the Company filed an Elimination of Certificate of Designation terminating the Series A Preferred Stock designation, with no shares outstanding on the Effective Date.¶3
The redemption was funded with a portion of the net proceeds from the Company’s $15 million registered direct offering announced on September 9, 2026.¶4
On September 15, 2026, Jaguar Health filed a Certificate of Elimination covering its Specified Series Preferred Stock, returning those shares to authorized but undesignated preferred stock.¶2
All outstanding shares of the Specified Series Preferred Stock had been converted, exchanged or otherwise disposed of before September 15, 2026, and no such shares were outstanding immediately before filing.¶3
On September 17, 2026, the Company effected a 1-for-15 reverse stock split of its issued and outstanding common stock.¶1
Upon completion of the Reverse Stock Split, the Company had approximately 520,088 outstanding shares of Common Stock.¶1
On September 18, 2026, GT Biopharma and a new purchaser amended the securities purchase agreement, increasing the offering to 8,611.111 shares of Preferred Stock with an aggregate stated value of $8,611,111.11 for an aggregate purchase price of $7,750,000.¶2¶3
Each purchaser may elect to purchase Preferred Stock with an aggregate stated value of up to $34,675,615 for an aggregate purchase price of $31,208,054, subject to adjustments.¶4
On September 18, 2026, the new purchaser joined the registration rights agreement on the same terms and conditions.¶5
On September 18, 2026, the Company filed a Certificate of Increase raising the designated Series M Preferred Stock from 41,778 shares to 43,287 shares.¶1
On September 21, 2026, Axos Bank completed its previously announced acquisition of IRAs deposited into associated savings and certificate of deposit accounts from Capital One.¶1
The Bank acquired approximately $1.9 billion of IRA deposits from Capital One and received cash for the aggregate deposit balance, less a negotiated premium.¶1
